Stock Evaluator: Sinopharm Group Co. Ltd. (SHTDY)
Sinopharm Group Co. Ltd. SHTDY
$11.07
-0.11
-1.01%
July 31, 2026 3:58:26 PM
EST
Volume: 76,526
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People’s Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Financial Summary
| Share Statistics | SHTDY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,916.6 | $1,742.7 | 72% |
|
| Shares Out (Mil) | 455.5 | 76.7 | 88% |
|
| Institutional Ownership | 50.0% | 89.7% | 30% |
|
| Float (Mil) | 1,274.6 | 49.4 | 93% |
|
| Beta | 0.44 | 0.82 | 24% |
|
| Avg Daily Volume (000s) | 128 | 521 | 39% |
|
| Price Change (52-week) |
(10.8%) | 78.7% | 37% |
|
| Growth | SHTDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.3% | 11.0% | 28% |
|
| Net Income (5yr) | (1.5%) | (0.7%) | 38% |
|
| EPS (5yr) | (1.6%) | 3.1% | 29 |
|
| Dividends (5yr) | (1.4%) | 0.0% | 56% |
|
| Cash Flow (5yr) | (20.1%) | (18.0%) | 33% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SHTDY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $83,259 | $1,456 | 98% |
|
| Net Income (TTM) (Mil) | $1,031 | $12 | 87% |
|
| EPS (TTM) | $0.329 | $0.300 | 50% |
|
| Operating Cash Flow (TTM) (Mil) | $2,355 | $138 | 89% |
|
| Net Cash Flow (TTM) (Mil) | ($1,385) | $8 | 2% |
|
| Long-Term Debt (Q1) (Mil) | $944 | $316 | 66% |
|
| Enterprise Value (Q1) (Mil) | $20,013 | $2,170 | 83% |
|
| Valuation | SHTDY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.85 | na |
|
| P/E | na | 26.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SHTDY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 7.2% | 27.8% | 7% |
|
| Net Margin | 1.2% | 1.1% | 35% |
|
| ROA | 1.8% | 1.8% | 54% |
|
| ROE | 8.8% | 7.1% | 54% |
|
| Liabilities to Assets | 65.9% | 59.9% | 61% |
|
| F-Score | na | 5 | na |
|
Sinopharm Group Co. Ltd. did not pass any screens on 7/31/2026.
